NCT00300586View on ClinicalTrials.gov

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

842

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
DRUG

observation

observation, second line chemotherapy if progression

DRUG

gemcitabine

1250 mg/m² D1, D8 q21 days

DRUG

erlotinib

150 mg daily

Trial Locations (1)

69317

Maurice PEROL, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT00300586 - IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter